(S)-1-Boc-3-Hydroxypiperidium CAS 143900-44-1

Description:

Chemical Name: (S)-1-Boc-3-Hydroxypiperidine

CAS: 143900-44-1

Chiral Puritas: >99.0% (GC)

Puritas chemica: >99.0% (GC)

Aspectus: pulveris vel Crystal

Medium Ibrutinib (CAS: 936563-96-1)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum	(S) -1-Boc-3-Hydroxypiperidine
Synonyma	(S) -1-(tert-Butoxycarbonyl) -3-Hydroxypiperidine;(S) -1-Boc-3-Piperidinol
CAS Number	143900-44-1
CATTUS Number	RF-CC299
Stock Status	In Stock, Productio Capacity 20 Tons/mense
Formulae hypotheticae	C10H19NO3
M. Pondus	201.27
Liquescens punctum	52.0~56.0℃
Solubilitas	Solutum in Methanol
Imprimis Rotationes [a]20/D	+9.0°~+11.0° (C=1 in Chloroform)
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba pulveris vel crystallis
Chiral Puritas	>99.5% (GC)
Puritas chemica	>99.5% (GC)
Aquae (KF)	≤0.50%
Methanol (GC)	≤50ppm
Ethanol (GC)	≤50ppm
DCM (GC)	≤500ppm
3-Hydroxypiperidine	≤0.10%
3-Hydroxypyridine	≤0.20%
1-Boc-3-Piperidone	≤0.10%
1-Boc-4-Hydroxypiperidine	≤0.10%
1.96 RRT	≤0.20%
Quis non specificatus immunditia	≤0.10%
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical Intermedia;Chiral Composita

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

(S) -1-Boc-3-Hydroxypiperidium (CAS: 143900-44-1) medium chiral magni momenti est pro synthesi Ibrutinib (CAS: 936563-96-1).Ibrutinib est genus tyrosine kinase bruton (BTK) inhibitoris, adhiberi potest ad curationem lymphocyticam longam leukemia (CLL) et pallium cellae lymphomae (MCL).MCL et CLL ad lymphoma B-celluli Hodgkin non pertinebant, quod difficile est curare et facile recurrere.Commune chemicum immunotherapyrum scopum non habet, saepe occurrit motus 3 vel 4 adversas.Ibrutinib et B lymphocytes oppugnare potuerunt cum BTK, quae ad informationem, differentiationem et transmissionem necessaria sunt, BTK actionem irreversibiliter inhibent, et tumorem cellularum proliferation et efficaciter superstes inhibent.Ibrutinib celeriter post administrationem oralis absorberi potuit, in 1~2h ad maximam unionem sanguinis, motus adversae unius vel duo pertinent, ergo Ibrutinib nova optio curationis CLL et MCL fiet.